We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05557045
Recruitment Status : Recruiting
First Posted : September 27, 2022
Last Update Posted : November 15, 2022
Sponsor:
Information provided by (Responsible Party):
Jazz Pharmaceuticals

Brief Summary:
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.

Condition or disease Intervention/treatment Phase
Advanced Cancer Metastatic Cancer Solid Tumor Drug: JZP815 Phase 1

Detailed Description:

This first-in-human study will consist of two parts: Part A and Part B.

Part A will characterize the safety and tolerability of JZP815, determine a maximum tolerated dose (MTD) and pharmacokinetics (PK) profile, and determine a recommended phase 2 dose (RP2D) to be further investigated in the Expansion phase (Part B).

Part B will further investigate the RP2D determined in Part A, and assess antitumor activity in various subsets of disease (based on mutation and/or tumor type) in which the mechanism of action of JZP815 is applicable.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway
Actual Study Start Date : October 10, 2022
Estimated Primary Completion Date : April 2028
Estimated Study Completion Date : April 2028

Arm Intervention/treatment
Experimental: Dose Exploration (Part A): JZP815
Participants who will receive JZP815 with a starting dose of 20 mg twice daily (BID).
Drug: JZP815
JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening.

Experimental: Expansion (Part B): JZP815
Participants with advanced or metastatic solid tumors who will receive JZP815 at the RP2D established in Dose Exploration (Part A).
Drug: JZP815
JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening.




Primary Outcome Measures :
  1. Number of Participants With Dose-Limiting Toxicities (Part A) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  2. Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  3. Change From Baseline in Hemoglobin (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  4. Change From Baseline in Absolute Neutrophil Count (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  5. Change From Baseline in Platelets (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  6. Change From Baseline in Hematocrit (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  7. Change From Baseline in Aspartate Aminotransferase (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  8. Change From Baseline in Alanine Aminotransferase (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  9. Change From Baseline in Creatinine (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  10. Change From Baseline in Total Bilirubin (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  11. Change From Baseline in Heart Rate (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  12. Change From Baseline in Blood Pressure (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  13. Number of Participants With Dose Interruptions and Reductions (Part A and B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  14. Objective Response Rate (as Defined by RECIST v1.1) (Part B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  15. Duration of Response (Part B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]

Secondary Outcome Measures :
  1. Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  2. Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  3. Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
    AUC from time 0 to infinity (AUCinf) and AUC during a dosing interval (AUCtau) will be assessed.

  4. Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  5. Pharmacokinetic Parameter Clearance (CL/F) of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  6. Pharmacokinetic Parameter Accumulation Ratio of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  7. Pharmacokinetic Parameter Apparent Volume of Distribution During Terminal Phase (Vz/F) of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  8. Pharmacokinetic Parameter Metabolite to Parent Ratio of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  9. Dose Proportionality of JZP815 and its Metabolites (Part A) [ Time Frame: Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose ]
  10. Objective Response Rate (as Defined by RECIST v1.1) (Part A) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  11. Progression-free Survival (Part B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]
  12. Overall Survival (Part B) [ Time Frame: Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant must be ≥ 18 years of age, at the time of signing the informed consent
  • Participants who have histological or cytological diagnosis of an advanced or metastatic solid tumor carrying a documented, clinically significant, MAPK pathway alteration
  • Participants must have exhausted all available standard of care therapies, or in the opinion of the investigator would be unlikely to tolerate or derive clinically meaningful benefit from available standard of care therapy
  • Performance status (ECOG) of 0 or 1, measured within 72 hours before start of treatment
  • Must have measurable disease by RECIST v1.1
  • Tumor must be safely amenable to core needle or excisional biopsy (applies only to participants enrolled in Pre-Expansion cohorts)
  • Adequate organ function
  • Expected life expectancy of at least 12 weeks
  • For each arm in Part B (Expansion), participant must be diagnosed with the tumor type(s) carrying the mutation(s) specified and meet protocol specified requirements for prior therapy
  • Male participants must agree to refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use contraception
  • Female participants are eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: is a women of nonchildbearing potential (WONCBP) or is a women of childbearing potential (WOCBP) and using a contraceptive method that is highly effective during the study intervention period and for at least 3 months after the last dose of study intervention and agrees not to donate eggs
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) within 3 days before the first dose of study intervention
  • Capable of giving signed informed consent

Exclusion Criteria:

  • Known uncontrolled brain metastases. Stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants, with no dose change in the previous 4 weeks, are permitted
  • Active fungal, bacterial and/or known viral infection including HIV or Hepatitis A, B, C
  • Concomitant malignancies or previous malignancies with less than 2 years disease-free interval at the time of enrollment, with the exception of non-metastatic, non-melanomatous skin cancers, carcinoma in-situ, melanoma in-situ, prostate cancer with undetectable PSA that are adequately treated
  • Has clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), QTc ≥ 470 msec, or serious cardiac arrhythmia requiring medication
  • Uncontrolled or severe intercurrent medical condition
  • Gastrointestinal condition that could impair absorption of study intervention or inability to ingest study intervention
  • In the judgement of the investigator, any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study
  • Received any cancer directed therapy (chemotherapy, hormonal therapy, biologic, etc.) within 28 days or 5 half-lives (whichever is shorter) of starting study intervention. Participants who have received radiotherapy must have recovered from acute toxicities associated with treatment.
  • Use of any products or medicines known to be strong or moderate inducers or inhibitors of CYP3A4, which cannot be discontinued at least 4 weeks or 5 half-lives (whichever is shorter) before starting study intervention, or planned use at any time during the study
  • Use of proton pump inhibitors and histamine-2 receptor antagonists, which cannot be discontinued at least 2 weeks before first dose, or planned use at any time during the study
  • Concurrent therapy with any other investigational agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05557045


Contacts
Layout table for location contacts
Contact: Clinical Trial Disclosure & Transparency 215-832-3750 ClinicalTrialDisclosure@JazzPharma.com

Locations
Layout table for location information
United States, Colorado
SCRI HealthOne Not yet recruiting
Denver, Colorado, United States, 80218
United States, Florida
Florida Cancer Specialists - Lake Nona Recruiting
Orlando, Florida, United States, 32827
Florida Cancer Specialists - Sarasota Recruiting
Sarasota, Florida, United States, 34232
United States, Pennsylvania
Sidney Kimmel Cancer Center Not yet recruiting
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
Tennessee Oncology - Nashville Recruiting
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Jazz Pharmaceuticals
Layout table for additonal information
Responsible Party: Jazz Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05557045    
Other Study ID Numbers: JZP815-101
First Posted: September 27, 2022    Key Record Dates
Last Update Posted: November 15, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jazz Pharmaceuticals:
Advanced Cancer
Metastatic Cancer
Solid Tumor
JZP815
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms
Neoplastic Processes
Pathologic Processes